Quest Diagnostics Incorporated DGX
259.65 USD +0.96 (+0.37%)
At closeNov 12, 2026, 5:48 PM EST
259.65 0.00 0.00%
After hours · Nov 12, 5:48 PM ET
258.46 Day range 261.95
171.18 52-week range 261.95
- YTD
- +49.63%
- 1 year
- +38.96%
News
zacks.com Here's Why Quest Diagnostics (DGX) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
prnewswire.com Quest Diagnostics Declares Quarterly Cash Dividend SECAUCUS, N.J., Nov. 10, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly…
prnewswire.com Quest Diagnostics to Speak at the 9th Annual Evercore Healthcare Conference SECAUCUS, N.J., Nov. 9, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief…
prnewswire.com Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference in London SECAUCUS, N.J., Nov. 9, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief…
benzinga.com Quest Diagnostics Bumps Guidance While Managing Quanum System Breach Quest Diagnostics tops Q3 estimates, raises full-year 2026 guidance, and addresses an unauthorized Quanum LSM cybersecurity event.
benzinga.com Quest Diagnostics Q3 2026 Earnings Call Transcript Quest Diagnostics (NYSE:DGX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Quest Diagnostics Discloses Unauthorized Access To Its Testing Management Platform Quanum LSM System; Company Promptly Initiated Its Cybersecurity Incident Response Procedures To Contain The Activity; Sees No Material Disruption On October 21, 2026, Quest Diagnostics Incorporated (the "Company") learned of unauthorized access to its Quanum LSM system, which certain clients use to place test orders, receive and look up…
benzinga.com Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.97-$10.17 to $10.21-$10.31 vs $10.15 Est Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.97-$10.17 to $10.21-$10.31 vs $10.15 analyst estimate..
benzinga.com Quest Diagnostics Raises FY2026 Adj EPS Guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 Est; Raises FY2026 Sales Guidance from $11.950B-$12.050B to $12.065B-$12.105B vs $12.001B Est Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $11.05-$11.25 to $11.25-$11.35 vs $11.19 analyst estimate. Raises FY2026 sales outlook from $11.950 billion-$12.050 billion to $12.065…- benzinga.com Quest Diagnostics Q3 Adj. EPS $3.00 Beats $2.86 Estimate, Sales $3.097B Beat $3.046B Estimate Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $2.86 by 4.9 percent. This is a 15.38 percent increase over earnings of $2.60…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
benzinga.com Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $260 Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.
benzinga.com CMS Targets $1 Billion in Annual Savings With new Medicare Lab Payment Rates — Here’s What Could Change in 2027 CMS proposes 2027 Medicare lab rates, estimating $1 billion in annual taxpayer savings as payments align with private rates.
benzinga.com Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
benzinga.com Why Vicor Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket Vicor jumped 11% premarket after raising Q3 growth guidance above 20%; TOPS, FBGL and QNME led other gainers.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 11.8% to $0.44 during Monday's after-market session. The company's market cap stands at $36.9 million. Evotec (NASDAQ:EVO) stock rose…- benzinga.com Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $260 Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $250 to $260.
- benzinga.com Quest Diagnostics Study Indicates That Nearly One In Three Patients With Antibodies Against Bacterium That Causes Lyme Disease Also Had Antibodies Against One Or More Additional Tick-Borne Pathogens New study by researchers from Quest Diagnostics (NYSE:DGX) and the University of North Carolina at Chapel Hill. Published in JAMA Network Open, the study, titled "Coseropositivity to Tick-Borne…
benzinga.com 10-Year Yield Tops 5%, Oil Storms Past $105: Stock Market Today The 10-year Treasury yield broke 5% for the first time since 2007 as WTI surged past $105 on Saudi pipeline outages, pressuring stocks ahead of the Fed.
benzinga.com UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $245 UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $245.- benzinga.com Quest Diagnostics Expands AD‑Detect Portfolio With Two New Blood‑Based Biomarker Tests To Broaden Access For Alzheimer’s Evaluation Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patientsQuest also launching a new multi-biomarker AD-Detect® lab-developed blood test with…
benzinga.com JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $250 JP Morgan analyst Lisa Gill maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $220 to $250.- benzinga.com Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260 Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $235 to $260.
benzinga.com Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $250 Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $225 to $250.
benzinga.com Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250 Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $230 to $250.
benzinga.com Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $255 Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $236 to $255.
benzinga.com Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidance gets a boost.
benzinga.com Lockheed Martin, Quest Diagnostics, Thermo Fisher Scientific And Other Big Stocks Moving Higher On Thursday U.S. stocks were down as Dow Jones fell 450 points on Thursday. Lockheed Martin (LMT) shares rose 11.4% on better-than-expected results. Other big gainers were NVE Corp (NVEC), Gibo Holdings Ltd…
benzinga.com Transcript: Quest Diagnostics Q2 2026 Earnings Conference Call Quest Diagnostics (NYSE:DGX) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…
benzinga.com Earnings Scheduled For July 23, 2026 Companies Reporting Before The Bell • Altisource Portfolio (NASDAQ:ASPS) is estimated to report quarterly earnings at $0.18 per share on revenue of $42.90 million. • Dime Commercial (NYSE:DCOM) is…- benzinga.com Quest Diagnostics Raises FY2026 Adj EPS Guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 Est; Raises FY2026 Sales Guidance from $11.780B-$11.900B to $11.950B-$12.050B vs $11.851B Est Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.63-$10.83 to $11.05-$11.25 vs $10.76 analyst estimate. Raises FY2026 sales outlook from $11.780 billion-$11.900 billion to $11.950…
- benzinga.com Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 Est Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.58-$9.78 to $9.97-$10.17 vs $9.60 analyst estimate..
- benzinga.com Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $3.12 per share which beat the analyst consensus estimate of $2.83 by 10.25 percent. This is a 19.08 percent increase over earnings of…
benzinga.com Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236 Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.- benzinga.com Quest Diagnostics Receives New York's Department of Health's Clinical Laboratory Evaluation Program Approval For Its Haystack Minimal Residual Disease Liquid Biopsy Test To Trace Residual Or Recurring Disease In Solid Tumor Cancers Patients Quest Diagnostics® (NYSE:DGX), a leading provider of diagnostic information services, today announced that the New York State Department of Health's (NYSDOH) Clinical Laboratory Evaluation Program…
- benzinga.com UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $220 UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $210 to $220.
benzinga.com These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings Quest Diagnostics (DGX) reported strong Q1 earnings, beating expectations and raising guidance. Analysts maintain positive outlook on stock.- benzinga.com Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $229 Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $224 to $229.
- benzinga.com Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $230 Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $225 to $230.
- benzinga.com Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $225 Truist Securities analyst David Macdonald maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $220 to $225.
benzinga.com Quest Diagnostics Gains Steam With Partnerships, Lifts Outlook Quest Diagnostics Q1 revenue grew 9.2% as organic volume surged. Discover how new partnerships and AI drove these solid financial results.
benzinga.com Valmont Industries Posts Upbeat Q1 Results, Joins UnitedHealth Group, Quest Diagnostics And Other Big Stocks Moving Higher On Tuesday - benzinga.com Quest Diagnostics Q1 2026 Earnings Call: Complete Transcript
- benzinga.com Earnings Scheduled For April 21, 2026
- benzinga.com Quest Diagnostics Raises FY2026 GAAP EPS Guidance from $9.45-$9.65 to $9.58-$9.78 vs $9.43 Est. Quest Diagnostics (NYSE:DGX) raises FY2026 GAAP EPS guidance from $9.45-$9.65 to $9.58-$9.78 vs $9.43 analyst estimate..
- benzinga.com Quest Diagnostics Raises FY2026 Adj EPS Guidance from $10.50-$10.70 to $10.63-$10.83 vs $10.55 Est; Raises FY2026 Sales Guidance from $11.700B-$11.820B to $11.780B-$11.900B vs $11.750B Est. Quest Diagnostics (NYSE:DGX) raises FY2026 Adj EPS guidance from $10.50-$10.70 to $10.63-$10.83 vs $10.55 analyst estimate. Raises FY2026 sales outlook from $11.700 billion-$11.820 billion to $11.780…
- benzinga.com Quest Diagnostics Q1 Adj. EPS $2.50 Beats $2.35 Estimate, Sales $2.895B Beat $2.827B Estimate. Quest Diagnostics (NYSE:DGX) reported quarterly earnings of $2.50 per share which beat the analyst consensus estimate of $2.35 by 6.38 percent. This is a 13.12 percent increase over earnings of $2.21…
- benzinga.com Evercore ISI Group Maintains In-Line on Quest Diagnostics, Lowers Price Target to $210 Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics (NYSE:DGX) with a In-Line and lowers the price target from $220 to $210.
- benzinga.com Quest Diagnostics Launches Gemini-Powered Quest AI Companion To Analyze Up To 5-Years Of Lab Results In MyQuest App New feature based on Google's Gemini seamlessly analyzes up to five years of personal lab data to help explain results and uncover potential health risksSECAUCUS, N.J., March 2, 2026 /PRNewswire/ --…
- benzinga.com Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $235 Mizuho analyst Ann Hynes maintains Quest Diagnostics (NYSE:DGX) with a Outperform and raises the price target from $210 to $235.